FDA Inspection 1338934 — Zhejiang Wild Wind Pharmaceutical Co., Ltd.
The FDA completed an inspection of Zhejiang Wild Wind Pharmaceutical Co., Ltd. on Sep 11, 2026 in Dongyang. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 11, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Dongyang (China)